- Notification that Quarterly Report will be submitted late (NT 10-Q)
August 16 2010 - 1:24PM
Edgar (US Regulatory)
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
OMB
APPROVAL
|
|
OMB
Number: 3235-0058
Expires:
May 31, 2012
Estimated
average burden
hours
per response2.50
|
|
FORM
12b-25
|
|
|
|
|
|
|
SEC
FILE NUMBER
|
|
|
001
32477
|
|
|
|
|
|
CUSIP
NUMBER
|
(Check
One)
:
|
¨
Form
10-K
¨
Form
20-F
¨
Form
11-K
x
Form
10-Q
¨
Form
N-SAR
¨
Form
N-CSR
|
88650T104
|
|
For
Period Ended:
June 30,
2010
|
|
|
|
|
|
o
|
|
Transition
Report on Form 10-K
|
|
o
|
|
Transition
Report on Form 20-F
|
|
o
|
|
Transition
Report on Form 11-K
|
|
o
|
|
Transition
Report on Form 10-Q
|
|
o
|
|
Transition
Report on Form N-SAR
|
|
|
|
|
|
For
the Transition Period Ended:
_____________________________
|
Read
attached instruction sheet before preparing form. Please Print
or Type.
Nothing
in this form shall be construed to imply that the Commission has verified
any information contained
herein.
|
If
the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
|
|
PART I -
REGISTRANT INFORMATION
Full
Name of Registrant
|
Tiens
Biotech Group (USA), Inc.
|
Former
Name if Applicable
|
|
Address
of Principal Executive Office
(Street and
Number)
|
No.
6, Yuanquan Road, Wuqing New-Tech Industrial Park
|
City,
State and Zip Code
|
Tianjin,
PRC 301700
|
|
PART
II
RULES
12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
x
|
(a)The
reason described in reasonable detail in Part III of this form could not
be eliminated without unreasonable effort or expense;
(b)The
subject annual report, semi-annual report, transition report on Form 10-K,
Form 20-F, 11-K, Form N-SAR or From N-CSR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed due
date; or the subject quarterly report or transition report on Form 10-Q or
subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due
date; and
(c)The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K,
10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
The quarterly report of Tiens Biotech
Group (USA), Inc. (the “Company”) on Form 10-Q could not be filed within the
prescribed time period due to the fact that the Company was unable to
finalize its financial results as well as the disclosure requirements of Form
10-Q without unreasonable expense or effort. As a result, the Company could not
solicit and obtain the necessary review of the Form 10-Q and signatures thereto
in a timely fashion prior to the due date of the report.
PART
IV
OTHER
INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
|
|
Mitchell
S. Nussbaum, Esq.
|
|
|
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months (or for such shorter) period
that the registrant was required to file such reports) been
filed? If answer is no, identify report(s).
|
x
Yes
¨
No
|
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
|
¨
Yes
x
No
|
|
If
so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
|
|
|
|
|
Tiens
Biotech Group (USA), Inc.
(Name of
Registrant as Specified in Charter)
Has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
August 16, 2010
|
By:
|
/s/ Jinyuan Li
Name: Jinyuan
Li
Title: Chief
Executive Officer
|
|
|
|
INSTRUCTION: The
form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative’s authority to sign on behalf of the registrant shall be filed
with the form.
|
ATTENTION
|
|
|
|
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations
(See 18 U.S.C. 1001).
|
2
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Tiens Biotech Grp. (Usa) Common Stock (American Stock Exchange): 0 recent articles
More News Articles